Abstract
INTRODUCTION: The management of allergic bronchopulmonary aspergillosis (ABPA) is complicated by prolonged, multi-drug regimens that carry a high risk of multi-system adverse drug reactions (ADRs). This complexity underscores the need for integrated, continuous pharmaceutical care to optimize safety and efficacy, yet standardized models for such care are lacking. CASE PRESENTATION: We report the case of a patient with ABPA and comorbid chronic hepatitis B, who had a history of failed ABPA therapy. During the current therapeutic course, the patient not only sequentially developed steroid-induced diabetes, drug-induced liver injury, hyperlactatemia, visual disturbances, phototoxicity, and hypokalemia but also progressed to treatment-dependent ABPA. The patient successfully completed the over-two-year protocol through a pharmacist-led full-course pharmaceutical care model that integrated regimen evaluation, efficacy monitoring, comprehensive adverse reaction management, discharge education, and follow-up. CONCLUSION: This case demonstrates that a full-course pharmaceutical care model enables timely detection and management of complex ADRs, optimizes therapeutic outcomes, and supports multidisciplinary decision-making. The model illustrates the pivotal role of the clinical pharmacist in improving medication safety and efficacy in ABPA, offering a replicable framework for promoting integrated, patient-centered care in pulmonary fungal diseases.